Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading CYPH daily closes…
Loading price history…
Pipeline assets
Sirexatamab
Phase 2 · ActiveModality: monoclonal antibody
Aliases DKN-01
Target DKK1
Indications
DKK1-high metastatic colorectal cancer (2L)(Phase 2)
Status note Anti-DKK1 mAb. Phase 2 DeFianCe study in 2L MSS CRC completed; FDA Type C alignment reached on a registrational Phase 3 design in DKK1-high 2L mCRC (~270 pts, dual primary endpoints).
Status note Preclinical anti-GDF15 antibody for cachexia-related indications. Development program wound down Jun 2025 as part of R&D wind-down; no partner-seeking or forward development described in filing.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.